Norflex (Orphenadrine Citrate) Controlled Substance Status in Washington State
Norflex (orphenadrine citrate) is NOT classified as a controlled substance in Washington State or at the federal level.
Regulatory Classification
Orphenadrine citrate is a skeletal muscle relaxant that does not fall under any schedule of the Controlled Substances Act 1. The FDA labeling makes no mention of controlled substance scheduling, and the drug is not subject to DEA regulatory control provisions that apply to scheduled medications 1.
Key Points About Norflex
Mechanism: Orphenadrine is indicated as an adjunct to rest and physical therapy for acute painful musculoskeletal conditions, though its exact mechanism is not clearly identified and may relate to analgesic properties rather than direct muscle relaxation 1
Prescribing Requirements: Unlike controlled substances, orphenadrine does not require:
- Triplicate prescription forms
- DEA registration for prescribing
- Special monitoring under Washington State's prescription monitoring program
- The regulatory oversight that applies to scheduled drugs 2
Clinical Context
While Washington State has implemented prescription monitoring programs for controlled substances 2, orphenadrine falls outside this regulatory framework. The 2022 CDC guidelines recommend skeletal muscle relaxants as appropriate pharmacologic treatment for conditions like acute low back pain 3, and orphenadrine can be prescribed without the restrictions that apply to controlled medications.
Prescribers in Washington State can write standard prescriptions for Norflex without controlled substance documentation or monitoring requirements.